| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 28.2MM | +11% |
| Gross Profit | 16.3MM | +11% |
| Cost Of Revenue | 11.8MM | +11% |
| Operating Income | 282K | -130% |
| Operating Expenses | 16MM | +2% |
| Net Income | -1.8MM | +47% |
| R&D | 3.1MM | +14% |
| G&A | 5.3MM | -9% |
| Marketing | 6.2MM | +9% |
| Amortization | 1.4MM | +2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO,
It hasn't been the best quarter for Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shareholders, since the share price has...
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 13-14, ...
HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024. Joining him will be Jennifer Cote, the Company’s Chief Financial Officer. Both presentations will be webcast live and can be accessed through the investor relations section
Key Insights The projected fair value for Harvard Bioscience is US$6.70 based on 2 Stage Free Cash Flow to Equity...
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2023 Earnings Call Transcript March 7, 2024 Harvard Bioscience, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and thank you for standing by. Welcome to Harvard Bioscience, Inc. Fourth Quarter 2023 Earnings […]
Q4 2023 Harvard Bioscience Inc Earnings Call
Modest Revenue Decline with Significant Gross Margin Expansion Amidst APAC Challenges
Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating income of $3.3 millionStrong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023. Jim Green, Chairma
Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analyticsHOLLISTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing prec